for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.BA

Latest Trade

2,810.00ARS

Change

31.50(+1.13%)

Volume

780

Today's Range

2,798.00

 - 

2,825.00

52 Week Range

1,829.00

 - 

3,025.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,778.50
Open
2,805.00
Volume
780
3M AVG Volume
248.41
Today's High
2,825.00
Today's Low
2,798.00
52 Week High
3,025.00
52 Week Low
1,829.00
Shares Out (MIL)
2,532.06
Market Cap (MIL)
198,336.10
Forward P/E
13.98
Dividend (Yield %)
3.32

Next Event

Dividend For MRK.N - 0.6500 USD

Latest Developments

More

Merck Sets Quarterly Dividend Of $0.65 Per Share

Merck Announces Phase 3 Keynote-355 Trial Met Primary Endpoint Of Overall Survival (Os) In Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed Pd-L1 (Cps ≥10)

Merck Says FDA Approves KEYTRUDA For Treatment Of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer In Combination With Chemotherapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Executive Chairman of the Board

Robert M. Davis

President, Chief Executive Officer, Director

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

2.08 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

46.2K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

5.519
Price To Earnings (TTM)
28.32
Price To Sales (TTM)
4.13
Price To Book (MRQ)
7.36
Price To Cash Flow (TTM)
18.39
Total Debt To Equity (MRQ)
115.99
LT Debt To Equity (MRQ)
89.08
Return on Investment (TTM)
11.21
Return on Equity (TTM)
8.02

Latest News

Latest News

Merck revenue beats estimates on Keytruda demand

Merck & Co Inc reported quarterly revenue on Thursday ahead of analysts' estimates, as a recovery in demand for its cancer drug Keytruda helped offset a hit to sales of some of the company's vaccines due to rising COVID-19 cases.

Merck profit nearly halves on Organon spin off

Merck & Co Inc on Thursday reported a 49% fall in second-quarter profit after it spun off its women's health and biosimilar assets into Organon in June. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

U.S. FDA approves Merck's Keytruda combo for early breast cancer treatment

Merck & Co Inc said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of a tough-to-treat breast cancer in combination with chemotherapy.

India's Hetero seeks emergency use nod for Merck's COVID-19 drug

India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.

Five Indian drugmakers to jointly start local trial of Merck & Co's COVID-19 drug

Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial in India for Merck & Co's experimental anti-viral drug to treat mild COVID-19 in non-hospitalised patients.

Five Indian drugmakers to jointly start trial of Merck & Co's COVID-19 drug

Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

U.S. signs $1.2 billion deal for 1.7 million courses of Merck's experimental COVID-19 drug

Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.

Merck says U.S. govt to buy about 1.7 mln courses of co's COVID-19 drug

Merck & Co Inc said on Wednesday the U.S. government has agreed to buy about 1.7 million courses of the company's experimental COVID-19 drug, molnupiravir, for about $1.2 billion, if it is authorized in the country. (Reporting by Manojna Maddipatla in Bengaluru; Editing...

AstraZeneca's Lynparza reduces relapse, death in breast cancer patients

AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.

Germany's Merck sees boost from labs supplies earnings

Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.

German labs supplier Merck raises forecast on strong first quarter

German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.

Congo declares end of Ebola outbreak that killed six

The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.

Congo declares end of Ebola outbreak that killed six

The Democratic Republic of Congo on Monday declared the end of an Ebola outbreak that infected 12 people in the eastern province of North Kivu and killed six of them.

U.S. drugmaker Merck sees bigger hit to full-year sales from pandemic

Merck & Co Inc said on Thursday it would take a bigger hit to sales this year than previously expected due to a resurgence in COVID-19 cases that has hurt demand for drugs that need to be given by doctors.

BRIEF-Merck Says Not Extending Trial For COVID-19 Drug Molnupiravir Into India At This Time

* MERCK & CO EXEC SAYS Q1 VACCINE SALES HURT BY RECOMMENDATIONS AGAINST CO-ADMINISTRATION OF COVID-19 VACCINES WITH OTHER SHOTS

Merck quarterly profit falls on COVID-19 hit

Merck & Co Inc reported a 1% fall in quarterly profit on Thursday, hurt by a drop in visits to the doctor's office because of a resurgence in COVID-19 cases at the beginning of the year in the United States. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila...

Merck taps five Indian drugmakers to expand COVID-19 drug production

Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.

Merck taps 5 Indian drugmakers to expand COVID-19 drug production

Merck & Co Inc said on Tuesday it had tied up with five generic drugmakers in India to expand access to molnupiravir, an experimental antiviral COVID-19 therapy it is developing with Ridgeback Biotherapeutics. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan...

Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patients

Merck & Co Inc on Thursday said it plans a large study of what could become the first pill to target the coronavirus in people at risk of severe COVID-19, but will no longer pursue use of the experimental antiviral drug in hospitalized patients.

WHO joins Europe, Merck in recommending against ivermectin for COVID-19

The World Health Organization (WHO) on Wednesday recommended against using generic anti-parasite drug ivermectin in patients with COVID-19 except for clinical trials, because of a lack of data demonstrating its benefits.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up